The major histocompatibility complex class II transactivator (CIITA) gene (16p13) has been reported to associate with susceptibility to multiple sclerosis, rheumatoid arthritis and myocardial infarction, recently also to celiac disease at genome-wide level. However, attempts to replicate association have been inconclusive. Previously, we have observed linkage to the CIITA region in Scandinavian type 1 diabetes (T1D) families. Here we analyze five Swedish T1D cohorts and a combined control material from previous studies of CIITA. We investigate how the genotype distribution within the CIITA gene varies depending on age, and the association to T1D. Unexpectedly, we find a significant difference in the genotype distribution for markers in CIITA (rs11074932, P ¼ 4 Â 10 À 5 and rs3087456, P ¼ 0.05) with respect to age, in the collected control material. This observation is replicated in an independent cohort material of about 2000 individuals (P ¼ 0.006, P ¼ 0.007). We also detect association to T1D for both markers, rs11074932 (P ¼ 0.004) and rs3087456 (P ¼ 0.001), after adjusting for age at sampling. The association remains independent of the adjacent T1D risk gene CLEC16A. Our results indicate an age-dependent variation in CIITA allele frequencies, a finding of relevance for the contrasting outcomes of previously published association studies.
INTRODUCTION
Type 1 diabetes (T1D) is a multifactorial disease where a number of genes are thought to be involved in regulating disease susceptibility. The major histocompatibility complex (MHC) is known to be the major T1D-susceptibility locus, accounting for approximately half of the genetic susceptibility to T1D. 1 The MHC region is thought to contain several susceptibility genes with two of the major ones being DRB1 and DQB1 1 in the MHC class II (MHC II) region. In the Caucasian population, there are two major susceptibility haplotypes for T1D, DRB1*03-DQA1*05:01-DQB1*02:01 and DRB1*04-DQA1*03:01-DQB1*03:02, and one protective haplotype, DRB1*15-DQA1*01:02-DQB1*06:02.
2,3
The regulation of the MHC II genes is mainly at the transcriptional level, and one of the crucial factors is the class II transactivator, encoded by the CIITA gene (16p13). The CIITA protein is a non-DNA-binding co-activator, which acts as a platform for the assembly of transcription factors that bind to MHC II promoters and control transcription. 4, 5 CIITA is regarded as the master control factor for the expression of MHC II genes, 6 and the lack of CIITA expression leads to an almost complete lack of MHC II expression. 7 Four independent and cell type-specific CIITA promoters (PI-PIV) have been identified in humans. 8 Promoter I (PI) mainly controls CIITA expression in myeloid dendritic cells and macrophages, whereas PIII is active in B cells, activated T cells and plasmacytoid dendritic cells, and the PIV promoter regulates IFNginducible CIITA expression in cells of non-hematopoetic origin and in thymic epithelium. 9 The function of the PII promoter in humans has not yet been fully characterized. 8 Because CIITA has a unique role in the control of MHC II expression and the MHC II locus is the major genetic determinant 1 Neuroimmunology Unit, Department of Clinical Neuroscience, Centre for Molecular Medicine, L8:05, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; for susceptibility to autoimmune diseases, CIITA is an interesting candidate gene in the study of autoimmune diseases like T1D. 10 Previously, we found genome-wide significant linkage on chromosome 16 in the region of CIITA to T1D (LOD ¼ 3.7), among T1D patients who also carry the DRB1*03 and DRB1*04 alleles. 11 The HLA association to T1D is also known to vary with age at onset, such that the association is stronger in younger patients compared with older patients. 3, 12, 13 Genome-wide significant association to celiac disease has recently been reported for markers in the CIITA gene. 14 In addition, increased susceptibility to myocardial infarction (MI), rheumatoid arthritis (RA) and multiple sclerosis (MS) has been demonstrated for a polymorphism (rs3087456) in the 5 0 region of type III CIITA. 15 However, this association has not always been replicated in later studies, and the outcome of the analysis is varying depending on which control group that has been used.
In this study, we test the hypothesis that CIITA is a T1D-susceptibility gene. In addition, we investigate if the allele distribution in the gene varies depending on age, and how this may affect the evidence for association.
RESULTS
Primary association to T1D in Diabetes incidence study in Sweden 2 (DISS2) The tag single-nucleotide polymorphisms (SNPs) described under Materials and methods were first genotyped in the DISS2 material, a T1D cohort consisting of DNA samples from 586 incident T1D patients and 836 controls. 16 Association was found in the area between PI and PIII. Five markers were added upstream of the PI promoter to better define the associated region in CIITA. One extra marker was also added in the CLEC16A gene, which is a known T1D-susceptibility gene that maps close to CIITA, 17 in order to exclude that association to T1D in the CIITA gene was due to linkage disequilibrium (LD) with this gene. The initial analyses indicated that several of the SNPs were associated to T1D with the most significant association being to rs11074932 (Supplementary Table S1 ). After correcting for multiple testing, only rs11074932 remained significant.
Age stratification Because of the inconclusive results when trying to replicate earlier association in the area, and different outcome depending on what control group that was used, we wanted to investigate if the age among the controls could have an effect on the association. The same three markers (rs11074932, rs3087456 and rs4774) used in the combined T1D study below was investigated. Control cohorts were collected as described in the Materials and methods section, and a test for trend showed that there is a significant trend where the frequency of the genotypes changes over age for two of the markers (rs11074932, P ¼ 4 Â 10
; rs3087456, P ¼ 0.05) among the controls (Figure 1 ). For both markers, the frequency of the major allele homozygote is increasing with age. The rs3087456 marker is significant only when the oldest age group (over 75 years of age) is included in the analysis. It should be noted that this group consist of several autopsy cases from a brain bank originally included in the Alzheimer's disease (AD) control group. No age-dependent effect was evident for the rs4774 marker.
Replication of age variation in an independent population-based cohort material The same markers in the CIITA gene were investigated in two cohorts of 25-and 75-year-old women (PEAK-25 and Osteoporosis Prospective Risk Assessment (OPRA)), respectively. Here we could confirm the significant variation in genotype for marker rs11074932 (P ¼ 0.006) and rs3087456 (P ¼ 0.007) with the minor allele homozygote genotype frequency decreasing with age.
Additionally, an earlier undiscovered variation could also be seen for the rs4774 marker (P ¼ 0.03), but here the minor allele is instead increasing with age ( Figure 2 and Table 1 ).
Age-corrected association to T1D in combined material To increase power to detect association to T1D, we combined cohorts from five T1D case-control studies and corrected for age at sampling using logistic regression. Because of the big discrepancies in age between the T1D cases and the other control cohorts, only T1D cohorts were included in this analysis.
Four SNPs (rs11074930, rs11074932, rs3087456 and rs4774) were chosen on the basis that they either had remained significant after correcting for age by matching each case to Figure 1 . Genotype distribution with age in CIITA among controls. Genotype frequencies in percent for (a) rs11074932, (b) rs3087456 and (c) rs4774 related to age group (number of individuals in parenthesis). P-value for respective genotype in test for trend-overage. For b, the P-value for the AA genotype is 0.09, if the oldest group (475 years of age) is removed.
two controls in an initial analysis in a smaller (DISS2) cohort (rs11074930, rs11074932) (Supplementary Table S1) or had been found associated to autoimmune disease in earlier publications (rs3087456, rs4774). 15, [18] [19] [20] Rs11074930 was found to deviate from Hardy-Weinberg equilibrium in a section of the control population and was discarded from further studies. Two markers showed some association (rs11074932, P ¼ 0.004 and rs3087456, P ¼ 0.001) ( Table 2 ) after correcting for age in the combined cohorts of T1D.
An age-stratified meta-analysis was performed for the associated markers to get an overview of the influence of different age groups and clarify the association. Only individuals under 40 years of age were included in this analysis because the majority of the patient falls into this group. We find that for both rs11074932 and rs3087456, heterozygotes are negatively associated, whereas major allele homozygotes are positively associated with T1D ( Figure 3 ). The association of CIITA SNPs to T1D was independent of CLEC16A, a nearby gene, which is an established T1D locus, 21 as association to CIITA SNPs remained after adding CLEC16A marker rs12708716 to the logistic regression model in the DISS2 cohort. In addition, an LD plot of the area was made in the DISS2 cohort, demonstrating that the rs12708716 SNP in CLEC16A is not in LD with any of our typed SNPs (Figure 4) . We also tested whether gender would affect the association, and added gender as a covariate in the logistic regression model. This did not alter the association.
Interaction analysis with HLA We also investigated if there was an interaction between T1D HLArisk alleles and CIITA. Because CIITA is a key protein in the control of expression of MHC class II alleles and we have previous findings Logistic regression analysis testing association of heterozygotes and minor allele homozygotes with major allele homozygotes as reference group, age at sampling was included as covariates.
d Logistic regression analysis testing association of presence of minor allele with major allele homozygotes as reference group, age at sampling was included as covariates.
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A Gyllenberg et al of increased linkage in DRB1*03/DRB1*04-positive patients in this region of chromosome 16, 11 we wanted to further investigate the role of interaction between CIITA and HLA haplotypes. Interaction analyses on both the additive and multiplicative scale was performed. These analyses were done for the presence of minor allele compared with major allele homozygotes. For both associated markers (rs11074932 and rs3087456), the results showed that there is a significant additive interaction for major allele homozygotes and absence of the DRB1*15 haplotype in relation to T1D, but not in any of the other HLA types. There was no interaction on the multiplicative scale (data not shown). This means that individuals risk for T1D associated with the joint lack of the protective DRB1*15 haplotype and presence of major allele homozygotes for any of these two SNPs are greater than the sum of the risk associated with DRB1*15 and CIITA SNPs individually ( Figure 5 ). The analysis shows that the association is depending on the absence of DRB1*15, which is not unexpected because the majority of T1D cases are DRB1*15 negative, and DRB1*15 is known as a strong protective factor for T1D.
The proportion of T1D is higher among DR15-negative individuals for major allele positive compared with major allele negatives for both markers (Po0.001 for rs11074932 and Po0.0003 for rs3087456), whereas no such difference is seen among DR15-positive individuals. This supports our conclusion that the CIITA association seems to be among DR15-negative individuals.
Because the association to T1D remained for two SNP markers (rs11074932 and rs3087456) even after controlling for age, gender and HLA, we suggest that these polymorphisms or other polymorphisms in close proximity are related to T1D susceptibility.
DISCUSSION
Given the pivotal role of CIITA for regulation of MHC class II gene transcription, 6 it is an obvious candidate for affecting susceptibility to autoimmune diseases known to be associated to MHC class II haplotypes. 22 Previous studies have reported positive, 19, 20 but also negative, 23, 24 results regarding association of CIITA to different autoimmune diseases.
In this study, we have performed LD mapping of the CIITA gene followed by an analysis of association to T1D. We identified a region extending between the PI and PIII promoters of the CIITA gene, which is modestly associated to T1D. This association remains significant after correcting for age, gender, HLA association and association to the CLEC16A gene, which is a nearby established T1D risk gene. 21 In a genome-wide association scan performed by the Wellcome Trust Case Control Consortium, 17 the 16p13 area was found to be significant associated to T1D. Age-stratified analysis of association in CIITA with T1D. Association in the combined cohort of five Scandinavian case-control studies for individuals o40 years of age, of rs11074932 and rs3087456 in CIITA with T1D. Meta-analysis of age groups with 5-year intervals and using the frequency of the genotypes for each marker.
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The CLEC16A gene has been thoroughly evaluated and found to be the major associated T1D risk gene in the area, and independent of the CIITA gene. 25 However, this does not rule out the possibility that CIITA can have a minor role as well at a more modest level. In the mentioned investigation of the area, there were inconclusive results regarding the association of CIITA, when significant association to T1D was found in a family material but not in the case-control cohort. 25 Our findings regarding the association of the CIITA gene to T1D is not genome-wide significant, but in the complex settings of the T1D, many genes with moderate influence are believed to have an impact on the etiology of the disease. This association between CIITA and T1D does, however, need to be confirmed in other materials to remain of interest.
We have in our study observed a significant difference in the genotype distribution for CIITA SNPs in a control cohort across different age groups, which we also confirm in an independent material of approximately 2000 individuals. The change in genotype frequency with age among controls in this gene can be one reason for the conflicting results of previously published CIITA case-control association studies. Thus, if one genotype or allele is less abundant among older control individuals, it could give a false association result for that genotype when compared with a younger patient group.
Possibly, this phenomenon may be relevant also for other genomic regions, and therefore suggest that proper matching of cases and controls with respect to age is important in genetic studies. This effect may not be evident when only analyzing an age-restricted sample material. For example, no age effect was found among the T1D patients. However, with most of the T1D patients having an onset before the age of 30, they cover only part of the age span included in the investigation. The variation for rs4774 with age was not discovered in our initial combined control material, where only 18 individuals over the age of 75 were genotyped for this marker, but seen in the cohort study including about 1000 75-year-old individuals. Possibly, the effect for this marker is more profound for the oldest age groups, and the same tendency is seen for the rs3087456 marker, where the significance level improves when adding additional 75-year-old or older individuals to the analysis. Although the discrepancies in results between association studies of the CIITA gene in part can be due to lack of statistical power to detect a small effect size, variability in outcome could also be affected by differences in age between patients and controls, a variable that often is not accounted for in genetic case-control studies.
There can be different underlying reason for an age effect on allele frequencies among the controls, which we will address in this discussion.
One reason could be population stratification, where the genotype frequencies vary among different population cohorts. Detailed data on ethnic origin was not available for all the cohorts included in this investigation, but when available, individuals with non-Scandinavian origin have been removed. The rs11074932 SNP is the marker varying most across the different age groups, with the TT genotype increasing with age at the expense of the other genotypes. The minor allele in the European and African populations (C) is the major allele in Japanese and Chinese populations. The distribution is similar for marker rs3087456, where the minor allele (G) in Europeans is the major allele in Japanese and African populations, but not much information about population diversity regarding genotypes for these two markers is available. Theoretically infiltration of these populations could affect our findings. However, because the controls used in this study were all collected from Swedish residents, and individuals with non-Scandinavian descent were removed, no or very few Japanese/Chinese or African individuals have to our knowledge been included. Also, one could argue that these are only minor immigrant groups in Sweden, and their participation in study cohorts like the one described here is likely to be small. Hence, the variation we see in our material is unlikely to depend solely on population heterogeneity.
A may be more reasonable and interesting theory concerns how the genotype affects health. It does not have to be a dramatic effect on longevity or survival, a small influence on the severity or recurrence of a common cold could be enough. If a certain genotype is associated with being healthier, it might be more likely that these individuals are included as healthy controls for a medical study. Such an effect may be more pronounced for older individuals and will result in a skewing of genotypes in the study cohorts. Blood donors are generally regarded as healthier than the general population. When we investigated the blood-donor control group from the MS cohort 1 (n ¼ 1217), we found that they have a lower minor allele frequency for rs3087456 (0.22) than the combined control material together (0.24). Similarly, the minor allele frequency for rs11074932 was 0.27 among blood donors compared with 0.28 in the whole material, regardless of age. This correlates with the findings that the older age groups in this study had a lower frequency of the minor allele homozygote genotype than did the younger groups. The minor allele of rs3087456 has been associated with lower expression of MHC class II chains after stimulation of leukocytes with interferon-g. 15 Possibly, a higher frequency of the minor allele for these markers leads to less expression of the CIITA gene and subsequently less MHC II molecules, which in turn could lead to less effective antigen presentation and immune defense. If this also leads to more severe or more occurrence of infections, it will affect the possibility for those individuals to become a blood donor or participate in a clinical study as a healthy control, maybe even more so if you are older. Theoretically, healthy older individuals in this study and blood donors are then expected to have increased expression of CIITA and therefore likely a more efficient clearance of infections.
A perhaps less likely explanation is that an infection or other environmental influence cause selection pressure for a certain genotype in the whole population, affecting the individual chance of survival. For this to occur, the infection in question must have conferred a high rate of mortality in young individuals, a scenario similar to what occurred due the Spanish flu epidemic.
Another reason for the variation of genotypes could be events that affect genotyping results. Because the genotyping of the different cohorts in this study has been performed with different methods, we had in some cases overlapping results for the same individuals from different genotyping platforms (RA cohort, dynamic allele-specific hybridization and Taqman technology). We could not find any major discrepancy in genotyping results in this test sample (1 mismatch out of 664 samples). Also, the RA cohort was re-genotyped with Taqman technology with a 100% concordance in results. It could be considered advantageous that different methods have been used, because it minimizes the effect of an introduced systematic error. All genotyping platforms used are well established and described.
Whatever the cause is, it is important to consider the effect it has on association studies and thoroughly choose well-matched controls in these cases. This variance could clearly affect the results of an association study that does not consider the age among the control group compared with the patient cohort.
The association found to T1D in this study is of moderate strength and not genome-wide significant. However, the importance of the CIITA gene's function in the immune system makes it plausible that it can have an effect on the pathogenesis of T1D. The two markers (rs3087456 and rs11074932) investigated here are in quite high LD, 76% (r 2 ), with each other (Figure 4) , and for both markers, it is the major allele homozygote that is associated to T1D. As there are earlier findings of lower expression of MHC class II chains after stimulation of leukocytes with interferon-g 15 for the minor allele of rs3087456, it is possible that a lower expression of CIITA and subsequently MHC II molecules could be protective to T1D in the way of less-efficient self-antigen presentation, and higher or 'normal' levels of CIITA correlating with the major allele genotype are involved in susceptibility. This correlates with our theory regarding the health aspect described above. Further functional studies are needed to investigate how different alleles may affect the expression of MHC class II in the setting of T1D.
In summary, we report an age-dependent variation in SNPs located in the CIITA gene among control materials. In addition, we demonstrate a significant, albeit modest association to T1D for SNPs located in the genomic region of the PI and PIII promoters of the CIITA gene after controlling for age. Taken together, these results suggest that replication of this association and other association studies in case-control materials should be performed with careful matching for age.
MATERIALS AND METHODS

Ethics statement
All included cohorts, patient material and analyses in this study were approved by the Regional Ethical Review Boards in the cities of Stockholm, Lund and Umeå in Sweden (www.epn.se). Informed consent from all study participants or their parents was obtained. Investigations were carried out according to the guidelines from the Declaration of Helsinki.
Subjects: T1D patients and controls
Diabetes incidence study in Sweden 1 (DISS1). The DISS1 cohort consists of DNA samples from 839 T1D patients and 625 sex, age and residencematched controls. Blood was collected from incidence patients from the DISS registry, diagnosed between 1987 and 1989, at the age of 15-36 years.
26 Figure 5 . Interaction between DRB1*15 and markers in CIITA. Lack of DRB1*15 together with the major allele homozygote increases the odds ratio (OR) for T1D. Error bars are 95% confidence interval of OR estimates. Attributable proportion (AP) is the proportion of the incidence among individuals exposed to both associated factors compared with the factors individually. The AP value is significant if separate from zero. HLA is coded as absence of HLA allele for DRB1*15. The CIITA SNPS were coded as absence of minor allele for both markers.
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In all, 667 of the patients were classified with T1D by the treating physician. Sufficient DNA was available for 431 T1D cases and 348 controls in this cohort; these were the individuals included in the current investigation.
Diabetes incidence study in Sweden 2. The DISS2 cohort consists of DNA samples from 778 incident diabetes patients aged 15-36 years and from the DISS registry during 1992 and 1993, and 836 sex-and age-matched controls. 16 In all, 586 of the patients were classified with T1D at follow-up and these subjects are included in this study.
Swedish childhood study (SV2).
A total of 497 cases of children between 0-14 years with newly diagnosed T1D were collected from the Swedish Childhood registry. Controls were geographically, gender and age matched to all cases 47 years of age (n ¼ 423). For patients o7 years, a control was selected among patients being treated at the hospital for reasons other than T1D (n ¼ 53). 27 Better diabetes diagnosis (BDD) study. A total of 2700 incident diabetes patients o18 years at diagnosis were collected between 2005 and 2009 from 40 pediatric clinics in Sweden for the BDD study. 28 Only patients diagnosed with T1D and with all parents and grandparents born in Scandinavia are included in this study.
Diabetes registry (DR) in Southern Sweden. A total of 804 T1D patients, 436 men and 368 women, with onset age between 1 and 75 years of age, from the Diabetes Registry in Southern Sweden, were all enlisted at the Department of Endocrinology at Malmö University Hospital, Sweden, and collected between 1996 and 2005. Additionally, 2312 healthy controls, 1695 men and 617 women between 45 and 75 years of age were added to the cohort. 29 Individuals of known non-Scandinavian origin were excluded (n ¼ 100).
Because of risk for overlap among patients in the DISS2 and DR cohorts, those individuals that could possibly occur in both cohorts were identified and removed from this study (n ¼ 73). To our knowledge, there are no other cohorts in this study that could be overlapping.
Extra control cohorts
Rheumatoid arthritis. A total of 1426 healthy controls matched to RA patients by age, sex and residential area. The recruitment of affected individuals and controls was described previously in connection with EIRA study. 30 In all, 373 of these controls were used in the SNP-tagging analysis. Individuals deviating in a principal component analysis or of known non-Scandinavian origin were excluded from this study (n ¼ 93). 31 Multiple sclerosis. From the Swedish MS 1 cohort, the control group consisted of 1215 healthy blood donors originating from Sweden or other Nordic countries. 32 From the Swedish MS 2 cohort, we used 663 controls matched for age, sex and residential location to newly diagnosed MS cases resident throughout Sweden in the EIMS studies. 33 All individuals of known nonScandinavian origin were excluded from the current study (n ¼ 190).
Myocardial infarction-SCARF. From the SCARF 15 study, the control group consists of 387 sex-and age-matched healthy persons between 40 and 60 years of age, and recruited from the general population of the same county as cases with MI, of self-reported Caucasian origin.
Alzheimer's disease-SNAC. A total of 424 healthy controls of 60-73 years of age, from an earlier study of AD, 34 randomly selected and sex-matched from 3500 individuals were included in the longitudinal study: the Swedish National Study on Aging and Care in Kungsholmen (SNACK), in Stockholm, Sweden. Also, originally added to this cohort are 39 individuals, which are autopsy cases from the Karolinska Brain Bank who died from cardiovascular or malignant diseases, between 56 and 91 years of age and without a medical history of dementia. The second cohort consists of 1010 healthy controls from the Malmö OPRA study, all aged 75 years and of Swedish or Northeuropean ancestry, randomly selected from the Malmö city files between 1995 and 1999. 36 Additional information regarding the cohorts is available in Supplementary Table S3 .
Genotyping methods
In the DISS2 cohort, the allelic discrimination method for SNPs TaqMan ABI 7900 (Applied Biosystems Inc, Stockholm, Sweden) 37 was used for all markers except for rs4774, rs3087456 and rs8052709 for which the dynamic allele-specific hybridization 38 method was used. SNP genotyping for DISS1 and SV2 studies was performed using the MassArray chip-based matrix-assisted laser desorption/ionization time-offlight mass spectrometer (Sequenom Inc., San Diego, CA, USA) using the Homogeneous MassEXTEND chemistry as described.
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T1D samples and controls from DR in Southern Sweden and the BDD cohort were genotyped with the TaqMan method.
In the gathered control material from RA, MS and MI, samples were genotyped as previously described. 15 Additional samples from these cohorts were genotyped with the TaqMan method. The controls from the AD cohort were genotyped with dynamic allele-specific hybridization.
In the PEAK-25 and OPRA cohorts, markers rs4774 and rs3087456 were genotyped with IPLEX (Sequenom Inc.) and rs11074932 was genotyped with Taqman. HLA typing HLA typing in the different cohorts were performed as follow; DISS1 and SV2: restriction fragment length polymorphism was used for DR typing, and genotyping for DQB1, DQA1 and DRB1 was performed with PCR amplification followed by dot blot hybridizations.
13
DISS2: HLA genotyping for DQB1, DQA1 and DRB1 was performed with PCR amplification followed by dot blot hybridizations and by restriction fragment length polymorphism as previously described, 13 except that allele-specific PCR amplification (PCR-SSP) of DRB1 alleles was also used. 40 BDD: A method based on an asymmetrical PCR and a subsequent hybridization of allele-specific probes was used, as described previously. 41 Established haplotypes in the European population were used to determine DR genotypes in the BDD cohort where only DQA1 and DQB1 were genotyped.
MS and RA: Genotyping by allele -pecific amplification as described earlier. 40 The other cohorts had no data concerning HLA status.
Tag SNPs and haplotype blocks
A total of 41 SNP markers were selected from dbSNP (http:// www.ncbi.nlm.nih.gov/SNP/) to be evenly spread across 66 428 bp of the CIITA gene (before PI to 3 0 untranslated region). Previously validated SNPs were chosen preferentially. The average marker spacing was 1468 bp (range 86-4030 bp). All SNPs were first genotyped in a selected cohort of 373 controls. Thirteen of the selected SNPs were non-polymorphic and one did not follow Hardy-Weinberg equilibrium and were discarded from further studies (Supplementary Table S1 ).
Genotypes from the remaining 28 SNPs were used to analyze LD block structure and to identify haplotype-tagging SNPs. The results from this analysis revealed five LD blocks (Supplementary Table S2 ), and common haplotypes in each block could be resolved by typing 1-3 haplotypetagging SNPs. LD blocks and haplotype-tagging SNPs were accomplished using the HapBlock analysis program. [42] [43] [44] The block partitioning algorithm was set as the dynamic programming algorithm, 42 the common haplotype method was used for block partitioning and the method for identifying haplotype-tagging SNPs was capable of identifying all common (45%) haplotypes.
Age stratification
Controls from studies of RA, MS, AD and MI together with T1D controls (DISS1, DISS2, SV2 and DR) were analyzed for three SNP markers, rs11074932 (C/T) 3747, rs3087456 (A/G) 7331 and rs4774 (C/G) 3317 controls (Supplementary Table S3 ).
The controls were divided into 15 5-year intervals with respect to age at sampling (0-4, 5-9 y 65-69 and 470).
Statistical analysis
Pearson's w 2 test was used to detect overall association, and logistic regression analysis using generalized linear modeling between the persons with diabetes and the general population was used to correct for the effect Age-dependent variation in CIITA A Gyllenberg et al of age and HLA on the CIITA association. When correcting for age in logistic regression, the age group 7 (30-35 years) was used as a reference group. In the logistic regression model where HLA was included as a factor, only individuals with data regarding DRB1*04 haplotype were included in these analyses to be able to compare results, because this was a limiting factor. HLA coding was otherwise defined as presence or absence of allele for DRB1*15 and DRB1*03, and for DRB1*04, only individuals with DRB1*04*DQB1-03:02 were considered positive for DRB1*04. The w 2 test for trend in proportions was used to detect the overall trend in variation of genotype over age. Pearson's w 2 test was also used to detect differences in genotype and allele frequencies between the two age groups in the population-based cohorts used for replication.
A joint age-stratified ('meta-analysis over age groups') test of association in CIITA with T1D in the combined cohort of five case-control studies was performed for the first eight age groups (0-39 years), using fixed effect Mantel-Haenszel analysis and Woolf's test for heterogeneity in R using the meta.MH command in the rmeta package (R package version 2.16. http://CRAN.R-project.org/package=rmeta).
In rs3087456_GG, age group 1 (0-4 years) was removed from the analysis due to heterogeneity between groups (P ¼ 0.04).
To investigate interaction between the CIITA gene and HLA haplotypes, departure from additivity was estimated by calculating attributable proportion due to interaction. These analyses were performed as described, 45 using the generalized linear modeling in R and the vcov command to get the covariance matrix. As suggested by Knol and VanderWeele, 46 the group with the lowest odds ratio when both factors are considered jointly have been used as reference group when calculating attributable proportion; however, the odds ratios plotted in Figure 5 are from the analysis when DR15 and CIITA minor allele positives were used as a reference group to clarify the interaction effect. The modeling included the SNP marker of investigation, as well as HLA haplotypes and age groups described as above.
All statistical analyses were performed in the statistical computer program R version 2.6.2, 47 except the initial association analysis, which was performed in Unphased 48 using the cocaphase command. An LD plot over the markers in the DISS2 cohort was performed in Haploview 4.2 ( Figure 4) . 49 
